# PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

> **NCT01581073** · PHASE3 · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 476 (actual)

## Conditions studied

- Chronic Kidney Disease
- Diabetes

## Interventions

- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT01581073
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-16
- **Primary completion:** 2017-12-07
- **Final completion:** 2017-12-07
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2018-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581073, "PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT01581073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*